Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Benitec Biopharma Inc.

NASDAQ: BNTC · Life Sciences · 7 alerts · CIK 1808898

Share price
$8.54Close, Nov 16
Market cap
$298M
Shares outstanding
34.88MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Benitec Biopharma Inc. filings on SEC EDGAR ↗

8:23 AM ET 10-Q
Financial Results

Benitec Biopharma Q1 2026 Results: Net Loss of $12.9M, Loss Widens

Benitec Biopharma reported a net loss of $12.9 million for the quarter ended September 30, 2026, compared to $9.0 million in the prior year period, primarily driven by a significant increase in research and development expenses for their BB-301 program. The company maintained a strong liquidity position with $176.4 million in cash and cash equivalents to fund ongoing clinical development.

Key figure
Net loss $12.9M
8:03 AM ET 8-K
Financial Results

Benitec Biopharma Financial Results

Benitec Biopharma reported financial results for its first fiscal quarter ended September 30, 2026, and announced a change in its fiscal year-end from June 30 to December 31. The company highlighted a 100% responder rate in its ongoing Phase 1b/2a study of BB-301 for OPMD and confirmed it remains on track to begin a pivotal trial in mid-2027.

Term
Q1 2027

“The consistency and durability of the clinical benefit observed to date continues to strengthen our conviction in the potential of BB-301 to meaningfully alter the course of OPMD-related dysphagia.”

Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer
4:06 PM ET 8-K
Financial Results

Benitec Biopharma Financial Results

Benitec Biopharma reported financial results for the fiscal year ended June 30, 2026, ending the period with approximately $180 million in cash. The company provided a clinical update on its BB-301 program for OPMD-related dysphagia, noting that Cohort 2 is fully enrolled and a pivotal study is planned for initiation in mid-2027 following a Type C meeting with the FDA.

Term
FY2026

“This has been an important year of clinical execution for Benitec and for the continued development of BB-301. Over the course of the year, we completed the follow-up of all six patients in Cohort 1 and fully enrolled Cohort 2, while continuing the regulatory interactions required to prepare BB-301 for advancement into a pivotal trial.”

Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer

“The consistency and durability of the clinical benefit observed to date, together with the discussions we have had with the FDA regarding pivotal study plans, continue to strengthen our conviction in the potential of BB-301 to meaningfully alter the course of OPMD-related dysphagia.”

Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.